From a therapeutic perspective, thalidomide, an effective treatment for DLE, has long been believed to exert its anti-inflammatory effects by targeting the 3’-untranslated region (3’-UTR) of TNF-α mRNA and inhibiting TNF-α production by monocytes (51, 52). The gene discussed is TNF; the disease is discoid lupus erythematosus.